

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7602948

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANANTH KARUMANCHI	06/30/2022
RECEIVING PARTY DATA	
Name:	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Street Address:	330 BROOKLINE AVENUE
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02205
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17846526
Application Number:	63214224
CORRESPONDENCE DATA	
Fax Number:	(857)300-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(857) 300-4000
Email:	leslie.roberts@lathropgpm.com, internalip@lathropgpm.com
Correspondent Name:	LATHROP GPM LLP
Address Line 1:	28 STATE STREET
Address Line 2:	7TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	719170 AND 727517 - 2OF2
NAME OF SUBMITTER:	JAMES H. VELEMA, ESQ.
SIGNATURE:	/James H. Velema/
DATE SIGNED:	10/21/2022
Total Attachments: 5	
source=728301- UM9-267 Family - Executed Assignment - BIDMC#page1.tif	
source=728301- UM9-267 Family - Executed Assignment - BIDMC#page2.tif	
source=728301- UM9-267 Family - Executed Assignment - BIDMC#page3.tif	
source=728301- UM9-267 Family - Executed Assignment - BIDMC#page4.tif	

ASSIGNMENT

WHEREAS, I, **Ananth Karumanchi** of Chestnut Hill, MA, have invented a certain new and useful invention, described in the patent applications identified in Exhibit A hereto; and

WHEREAS, **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.**, a corporation having its principal place of business at 330 Brookline Avenue, Boston, Massachusetts, 02205, United States, is desirous of acquiring all rights, title and interest in and to said inventions, said applications, and in and to any and all Letters Patents which may be granted for or upon said invention and applications in the United States of America and anywhere in the world.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, I, **Ananth Karumanchi**, have sold, assigned and transferred, and by these presents to sell, assign and transfer unto the said **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.**, the full and exclusive right, title and interest, throughout the world, in, to and under the following:

- (a) the inventions as set forth and described, for example, in the patent application specifications identified in Exhibit A;
- (b) all patent applications identified in Exhibit A;
- (c) any and all patent applications, including Patent Cooperation Treaty (PCT) applications, directed to the inventions as set forth and described, for example, in the patent application specifications identified in Exhibit A;
- (d) any and all refilings, divisions, continuations, and continuations-in-part of those patent applications;
- (e) any and all patents of the United States of America which may issue from any of the items in Exhibit A;
- (f) any and all reissue and reexamination certificates of those patents;
- (g) any and all applications for the inventions filed in any and all countries foreign to the United States of America;


- (h) any and all refilings, divisions, and continuations of those foreign-filed applications;
- (i) any and all patents, certificates, and registrations of countries foreign to the United States of America which may issue from those foreign-filed applications, refilings, divisions, and continuations;
- (j) any and all extensions of, and additions to, the foreign-filed applications and patents, certificates, and registrations related thereto;
- (k) the right to claim priority to any of the foregoing; and
- (l) any and all claims, causes of action, and damages for past, present, and future infringement or other unauthorized use of the above items, along with the right to sue and to collect damages and other relief from any and all parties.

I, **Ananth Karumanchi**, further agree that I will promptly execute and deliver to **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.** or its legal representatives any and all papers, instruments, and affidavits required to apply for, obtain, maintain, issue, and enforce all of the items listed above.

All of the above shall be held and enjoyed by **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.**, and its successors, legal representatives, and assigns for their own use and benefit, for the full term for which the protections listed above may be granted, and I, **Ananth Karumanchi**, authorize and request the Commissioner of Patents and Trademarks of the United States and of all foreign countries to issue any Patents granted for said inventions, whether on an application for said invention set forth in Exhibit A, or on any subsequently filed provisional, non-provisional, divisional, continuation, continuation-in-part, reissue, or other related application, to **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.**, its successors and assigns, as the assignee of their entire interest in said inventions and applications.

Assignor:

Ananth Karumanchi



Signature

06/30/22

Date:

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:


WITNESS

LOS ANGELES, CALIFORNIA

Signed At (City/State)

Dongsheng Zhang

Name



Signature

Date

6/30/2022

Assignee:

BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

Catherine Lenich

Signature

July 6, 2022

Date:

Catherine Lenich, PhD. – BIDMC Authorized
Signer

Name and Title: Technology Licensing Officer

Signed in my presence and acknowledged to be an assignment of the application herein
above referred to:

WITNESS

Boston, Massachusetts

Signed At (City/State)

Derek Sanchez

Name

Derek Sanchez

Signature

July 6, 2022

Date

Attorney Docket: 719170: UM9-267-1
728301: UM9-267
727517: UM9-267PC

Exhibit A

Assigned Patents and Patent Applications

**OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR
TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS**

U.S. Patent Application Serial No. 17/846,526, filed June 22, 2022
International Patent Application No. PCT/US2022/034461, filed June 22, 2022
U.S. Provisional Patent Application Serial No. 63/214,224, filed June 23, 2021

49190544v1